ESC 2020 During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes.
ESC 2020 The EAST-AFNET4 trial showed that patients with early AF and CV conditions benefit from early rhythm control therapy compared to patients who received standard therapy.
ESC 2020 Prof. Kirchhof shares the findings of the EAST-AF NET 4 trial, which evaluated the effect of early rhythm control in patients who were recently diagnosed with AF compared to usual care.
This expanded analysis of the CABANA trial showed that catheter ablation reduced symptomatic and asymptomatic AF recurrence and AF burden as compared to drug therapy over a 5-year follow-up period.
This retrospective cohort study used longitudinal data from 4 European health care databases to compare the risk of major bleeding in DOAC and VKA users with nonvalvular atrial fibrillation (NVAF).
This analysis of the REGARDS study showed that AF patients without CV comorbidities had no increased risk of stroke compared to individuals without AF or CV comorbidities.
In a study of acute HF patients in a Korean registry, AF was more prevalent with increasing EF, and associated with increased CV and total mortality in HFpEF patients and increased risk of stroke in HFrEF and HFpEF patients.
ACC 2020 Oral anticoagulant monotherapy reduced bleeding compared to anticoagulant therapy plus clopidogrel, without increasing ischemic events in AF patients undergoing TAVI.
ACC 2020 The POPular TAVI trial showed that OAC alone compared to OAC plus clopidogrel reduced bleeding and did not increase thrombotic events in AF patients undergoing TAVI.
This cluster randomized, non-inferiority trial showed that integrated care for elderly AF patients in a primary care setting led to a 45% reduction in all-cause mortality compared with usual care.
Although DOACs are safe and effective in AF patients, there are remaining challenges in prescribing DOACs. Freek Verheugt and John Eikelboom discuss 3 topics: underdosing, underuse and antidotes. With poll
The SGLT2 inhibitor dapagliflozin reduced time to first event of atrial fibrillation and atrial flutter as well as total events in T2DM patients, shown in a post-hoc analysis of the DECLARE-TIMI 58 trial.